These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent. Ahmed WH Expert Rev Med Devices; 2007 Mar; 4(2):117-20. PubMed ID: 17359218 [TBL] [Abstract][Full Text] [Related]
5. [Position paper on the use of drug eluting stents in coronary heart disease]. Mudra H; Bode C; Grube E; de Haan F; Levenson B; Schuler G; Silber S; ; Z Kardiol; 2004 May; 93(5):416-22. PubMed ID: 15160279 [No Abstract] [Full Text] [Related]
6. Regulatory issues facing the development of drug-eluting stents: a US FDA perspective. Boam AB Expert Rev Med Devices; 2006 May; 3(3):297-300. PubMed ID: 16681451 [TBL] [Abstract][Full Text] [Related]
7. Drug eluting stents. Panescu D IEEE Eng Med Biol Mag; 2004; 23(2):21-3. PubMed ID: 15264463 [No Abstract] [Full Text] [Related]
9. Drug-eluting coronary stents: many meta-analyses, little benefit. Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727 [TBL] [Abstract][Full Text] [Related]
10. [The Nordic Bifurcation Study. Randomized study on the question of optimal stenting technique for bifurcating stenosis]. Herz; 2006 May; 31(3):257. PubMed ID: 17431944 [No Abstract] [Full Text] [Related]
11. Programmable elution profile coating for drug eluting stents. Al-Lamee K Med Device Technol; 2005 Mar; 16(2):12-5. PubMed ID: 15828493 [TBL] [Abstract][Full Text] [Related]
12. Is there any place for oral anti-restenotic treatment in the era of drug eluting stents? Gershlick AH Heart; 2005 Nov; 91(11):1377-9. PubMed ID: 16230428 [TBL] [Abstract][Full Text] [Related]
14. [Drug-eluting coronary stents and drug eluting balloon catheters: summary of the position papers of the DGK]. Silber S; Borggrefe M; Böhm M; Hoffmeister HM; Dietz R; Ertl G; Heusch G Clin Res Cardiol; 2008 Aug; 97(8):548-63. PubMed ID: 18726643 [No Abstract] [Full Text] [Related]
15. Modelling drug elution from stents: effects of reversible binding in the vascular wall and degradable polymeric matrix. Borghi A; Foa E; Balossino R; Migliavacca F; Dubini G Comput Methods Biomech Biomed Engin; 2008 Aug; 11(4):367-77. PubMed ID: 18568831 [TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL; Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853 [TBL] [Abstract][Full Text] [Related]
17. Do the benefits outweigh the risks with drug-eluting stents? Kløw NE Scand Cardiovasc J; 2007 Jan; 41(1):8-9. PubMed ID: 17365970 [No Abstract] [Full Text] [Related]
18. The future of CART in the era of drug eluting stents: "It's not over until it's over". Counterpoint. Tripuraneni P Brachytherapy; 2003; 2(2):74-6. PubMed ID: 15062143 [No Abstract] [Full Text] [Related]
19. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale. Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384 [TBL] [Abstract][Full Text] [Related]